Literature DB >> 10389984

Vesnarinone and glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice.

Y Honma1, Y Yamamoto-Yamaguchi, Y Kanatani.   

Abstract

Vesnarinone, an oral cardiotonic, inhibited the growth of several human non-small cell lung carcinoma cell lines, and its anti-proliferative effects in vitro and in vivo were greatly enhanced by combination with glucocorticoids, but not other steroids. Simultaneous treatment with vesnarinone and dexamethasone is the most effective to evoke the synergistic effect in the growth inhibition of lung carcinoma EBC-1 cells. Dexamethasone and other glucocorticoids induced morphological changes in EBC-1 cells and these agents together with vesnarinone induced alkaline phosphatase activity, which is a typical marker of type II pneumocyte maturation. This treatment arrested the growth of the cells at the G1 phase, indicating that this treatment is cytostatic rather than cytotoxic. These results suggest that vesnarinone plus glucocorticoid might be useful in lung cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389984      PMCID: PMC2363000          DOI: 10.1038/sj.bjc.6690327

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Premature delivery of foetal lambs infused with glucocorticoids.

Authors:  G C Liggins
Journal:  J Endocrinol       Date:  1969-12       Impact factor: 4.286

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Acceleration of appearance of pulmonary surfactant in the fetal lamb by administration of corticosteroids.

Authors:  R A DeLemos; D W Shermeta; J H Knelson; R Kotas; M E Avery
Journal:  Am Rev Respir Dis       Date:  1970-09

4.  Specific enzymatic dephosphorylation of the retinoblastoma protein.

Authors:  J W Ludlow; C L Glendening; D M Livingston; J A DeCarprio
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

5.  Modulation of differentiation and proliferation in human colon carcinoma cells by transforming growth factor beta 1 and beta 2.

Authors:  S Chakrabarty; D Fan; J Varani
Journal:  Int J Cancer       Date:  1990-09-15       Impact factor: 7.396

6.  Transforming growth factor beta and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of human monocytoid leukemia cells.

Authors:  Y Kanatani; T Kasukabe; J Okabe-Kado; S Hayashi; Y Yamamoto-Yamaguchi; K Motoyoshi; N Nagata; Y Honma
Journal:  Cell Growth Differ       Date:  1996-02

7.  Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide.

Authors:  P Schroy; J Rifkin; R J Coffey; S Winawer; E Friedman
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

8.  Regulation of cell cycle progression and nuclear affinity of the retinoblastoma protein by protein phosphatases.

Authors:  A S Alberts; A M Thorburn; S Shenolikar; M C Mumby; J R Feramisco
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

9.  Inhibition and promotion of differentiated-like phenotype of a human lung carcinoma in athymic mice by natural and recombinant forms of transforming growth factor-beta.

Authors:  D R Twardzik; J E Ranchalis; J M McPherson; Y Ogawa; L Gentry; A Purchio; E Plata; G J Todaro
Journal:  J Natl Cancer Inst       Date:  1989-08-02       Impact factor: 13.506

10.  Phenotypic modification of human glioma and non-small cell lung carcinoma by glucocorticoids and other agents.

Authors:  J S McLean; M C Frame; R I Freshney; P F Vaughan; A E Mackie; I Singer
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

View more
  1 in total

1.  Gene expression profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic leukemia cells.

Authors:  Lijun Yang; Hongshan Zhao; Shi-Wu Li; Kim Ahrens; Christine Collins; Sarah Eckenrode; Qing-guo Ruan; Richard A McIndoe; Jin-Xiong She
Journal:  J Mol Diagn       Date:  2003-11       Impact factor: 5.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.